Literature DB >> 10798472

Mild cognitive impairment: potential pharmacological treatment options.

B B Sherwin1.   

Abstract

Both mild cognitive impairment and age-associated memory impairment are terms used to describe memory decline in otherwise healthy, intellectually intact individuals aged older than 50 years. It is estimated that up to 38% of the middle-aged and older population fulfill diagnostic criteria for this condition. Although the memory deficits observed in these individuals are fairly mild, they can interfere with day-to-day functioning. This article presents a review of the types of memory decline observed in older people, the diagnostic criteria used to define memory decline, the physiological and morphological brain changes that accompany aging, and the potential pharmacological treatment options, focusing on agents that have been evaluated in mildly cognitively impaired or normal older populations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10798472     DOI: 10.1111/j.1532-5415.2000.tb04703.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  11 in total

1.  Quantitative MRI of Perivascular Spaces at 3T for Early Diagnosis of Mild Cognitive Impairment.

Authors:  M Niazi; M Karaman; S Das; X J Zhou; P Yushkevich; K Cai
Journal:  AJNR Am J Neuroradiol       Date:  2018-08-09       Impact factor: 3.825

2.  The utility of a brief memory screen in the diagnosis of mild memory impairment in the elderly: preliminary study.

Authors:  David A Loewenstein; Amarilis Acevedo; Joscelyn Agron; Raymond Ownby; William Barker; Sylvia Strauman; Ranjan Duara
Journal:  Am J Geriatr Psychiatry       Date:  2009-05       Impact factor: 4.105

3.  Dual-task performance is associated with brain MRI Morphometry in individuals with mild cognitive impairment.

Authors:  Carissa Grijalva; Nima Toosizadeh; Jacob Sindorf; Ying-Hui Chou; Kaveh Laksari
Journal:  J Neuroimaging       Date:  2021-03-30       Impact factor: 2.486

4.  Therapeutic approaches to age-associated neurocognitive disorders.

Authors:  R O'Hara; C Derouesné; K N Fountoulakis; J A Yesavage
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

Review 5.  Brain pathological changes during neurodegenerative diseases and their identification methods: How does QSM perform in detecting this process?

Authors:  Farzaneh Nikparast; Zohreh Ganji; Mohammad Danesh Doust; Reyhane Faraji; Hoda Zare
Journal:  Insights Imaging       Date:  2022-04-13

6.  Quantitative susceptibility mapping to evaluate the early stage of Alzheimer's disease.

Authors:  Hyug-Gi Kim; Soonchan Park; Hak Young Rhee; Kyung Mi Lee; Chang-Woo Ryu; Sun Jung Rhee; Soo Yeol Lee; Yi Wang; Geon-Ho Jahng
Journal:  Neuroimage Clin       Date:  2017-08-24       Impact factor: 4.881

7.  Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial.

Authors:  Hee-Yeon Shin; Ha-Ri Kim; Geon-Ho Jahng; Chul Jin; Seungwon Kwon; Seung-Yeon Cho; Seong-Uk Park; Woo-Sang Jung; Sang-Kwan Moon; Chang-Nam Ko; Jung-Mi Park
Journal:  BMC Complement Med Ther       Date:  2021-10-07

Review 8.  Mild cognitive impairment: conceptual issues and structural and functional brain correlates.

Authors:  Andrew J Saykin; Heather A Wishart
Journal:  Semin Clin Neuropsychiatry       Date:  2003-01

9.  Neural correlates of true and false memory in mild cognitive impairment.

Authors:  Catherine M Sweeney-Reed; Patricia M Riddell; Judi A Ellis; Jayne E Freeman; Slawomir J Nasuto
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

10.  The melatonin metabolite N1-acetyl-5-methoxykynuramine facilitates long-term object memory in young and aging mice.

Authors:  Hikaru Iwashita; Yukihisa Matsumoto; Yusuke Maruyama; Kazuki Watanabe; Atsuhiko Chiba; Atsuhiko Hattori
Journal:  J Pineal Res       Date:  2020-11-20       Impact factor: 13.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.